Based on the Tscan Therapeutics Inc stock forecast from 6 analysts, the average analyst target price for Tscan Therapeutics Inc is USD 9.90 over the next 12 months. Tscan Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Tscan Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Tscan Therapeutics Inc’s stock price was USD 1.31. Tscan Therapeutics Inc’s stock price has changed by -5.07% over the past week, +0.77% over the past month and -85.33% over the last year.
No recent analyst target price found for Tscan Therapeutics Inc
No recent average analyst rating found for Tscan Therapeutics Inc
Company Overview Tscan Therapeutics Inc
There is no Profile data available for TCRX. Read Less
There is no Profile data available for TCRX.
N/A
N/A
0
N/A
USD
United States
Adjusted Closing Price for Tscan Therapeutics Inc (TCRX)
Loading...
Unadjusted Closing Price for Tscan Therapeutics Inc (TCRX)
Loading...
Share Trading Volume for Tscan Therapeutics Inc Shares
Loading...
Compare Performance of Tscan Therapeutics Inc Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for TCRX
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To Tscan Therapeutics Inc (Sector: Others )
Frequently Asked Questions About Tscan Therapeutics Inc (TCRX) Stock
Based on ratings from 6 analysts Tscan Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 10 buy, sell and hold ratings.
TCRX stock's dividend yield is 672.60%.
Our analysis grades TCRX stock's dividend yield at A+. This means that TCRX stock's dividend yield is above 100% of the stocks in the Others sector in the NSD exchange.
Based on this TCRX may be a good dividend stock for its sector.
Based on targets from 6 analysts, the average taret price for TCRX is USD 9.90 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on TCRX's stock to indicate if its overvalued.
The last closing price of TCRX's stock was USD 1.31.
The most recent market capitalization for TCRX is USD 0.82B.
Based on targets from 6 analysts, the average taret price for TCRX is projected at USD 9.90 over the next 12 months.
This means that TCRX's stock price may go up by +655.73% over the next 12 months.
We can't find any ETFs which contains Tscan Therapeutics Inc's stock.
As per our most recent records Tscan Therapeutics Inc has 0 Employees.
Sorry we do not have any infomation available on Tscan Therapeutics Inc's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Tscan Therapeutics Inc (TCRX) Stock
Based on ratings from 6 analysts Tscan Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 10 buy, sell and hold ratings.
TCRX stock's dividend yield is 672.60%.
Our analysis grades TCRX stock's dividend yield at A+. This means that TCRX stock's dividend yield is above 100% of the stocks in the Others sector in the NSD exchange.
Based on this TCRX may be a good dividend stock for its sector.
Based on targets from 6 analysts, the average taret price for TCRX is USD 9.90 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on TCRX's stock to indicate if its overvalued.
The last closing price of TCRX's stock was USD 1.31.
The most recent market capitalization for TCRX is USD 0.82B.
Based on targets from 6 analysts, the average taret price for TCRX is projected at USD 9.90 over the next 12 months.
This means that TCRX's stock price may go up by +655.73% over the next 12 months.
We can't find any ETFs which contains Tscan Therapeutics Inc's stock.
As per our most recent records Tscan Therapeutics Inc has 0 Employees.
Sorry we do not have any infomation available on Tscan Therapeutics Inc's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TCRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
